-
1
-
-
0028829525
-
The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma
-
Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109:1522-5.
-
(1995)
Gastroenterology
, vol.109
, pp. 1522-1525
-
-
Inoue, H.1
Mori, M.2
Honda, M.3
-
2
-
-
0030887192
-
HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer
-
Hoshino T, Seki N, Kikuchi M, et al. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997;70:631-8.
-
(1997)
Int J Cancer
, vol.70
, pp. 631-638
-
-
Hoshino, T.1
Seki, N.2
Kikuchi, M.3
-
3
-
-
0030972184
-
Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer
-
Maehara Y, Tomisaki S, Oda S, et al. Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer. Int J Cancer 1997;74:224-8.
-
(1997)
Int J Cancer
, vol.74
, pp. 224-228
-
-
Maehara, Y.1
Tomisaki, S.2
Oda, S.3
-
4
-
-
0028927607
-
The Fas death factor
-
Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
-
(1995)
Science
, vol.267
, pp. 1449-1456
-
-
Nagata, S.1
Golstein, P.2
-
5
-
-
0028092366
-
Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice
-
Mountz JD, Zhou T, Bluethmann H, et al. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol 1994;11:321-42.
-
(1994)
Int Rev Immunol
, vol.11
, pp. 321-342
-
-
Mountz, J.D.1
Zhou, T.2
Bluethmann, H.3
-
6
-
-
0028909197
-
Fas ligand mediates activation-induced cell death in human T lymphocytes
-
Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
-
(1995)
J Exp Med
, vol.181
, pp. 71-77
-
-
Alderson, M.R.1
Tough, T.W.2
Davis-Smith, T.3
-
7
-
-
0028238410
-
Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells
-
Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994;152:5624-32.
-
(1994)
J Immunol
, vol.152
, pp. 5624-5632
-
-
Daniel, P.T.1
Krammer, P.H.2
-
8
-
-
0028879109
-
Fas ligand-induced apoptosis as a mechanism of immune privilege
-
Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
-
(1995)
Science
, vol.270
, pp. 1189-1192
-
-
Griffith, T.S.1
Brunner, T.2
Fletcher, S.M.3
-
9
-
-
0028864778
-
A role for CD95 ligand in preventing graft rejection
-
Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
-
(1995)
Nature
, vol.377
, pp. 630-632
-
-
Bellgrau, D.1
Gold, D.2
Selawry, H.3
-
10
-
-
0030821649
-
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival
-
Stuart PM, Griffith TS, Usui N, et al. CD95 ligand (FasL)- induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402.
-
(1997)
J Clin Invest
, vol.99
, pp. 396-402
-
-
Stuart, P.M.1
Griffith, T.S.2
Usui, N.3
-
11
-
-
0030903088
-
Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immuno-suppression
-
Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997;46:317-22.
-
(1997)
Diabetes
, vol.46
, pp. 317-322
-
-
Korbutt, G.S.1
Elliott, J.F.2
Rajotte, R.V.3
-
12
-
-
0030017476
-
Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
-
Lau HT, Yu M, Fontana A, et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;270:109-12.
-
(1996)
Science
, vol.270
, pp. 109-112
-
-
Lau, H.T.1
Yu, M.2
Fontana, A.3
-
13
-
-
0030857077
-
Inhibition of the alloantibody response by CD95 ligand
-
Arai H, Chan SY, Bishop DK, et al. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997;3:843-8.
-
(1997)
Nat Med
, vol.3
, pp. 843-848
-
-
Arai, H.1
Chan, S.Y.2
Bishop, D.K.3
-
14
-
-
0029808372
-
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
-
O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
-
(1996)
J Exp Med
, vol.184
, pp. 1075-1082
-
-
O'Connell, J.1
O'Sullivan, G.C.2
Collins, J.K.3
-
15
-
-
10544232277
-
Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
-
Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
-
(1996)
Science
, vol.274
, pp. 1363-1366
-
-
Hahne, M.1
Rimoldi, D.2
Schroter, M.3
-
16
-
-
16144363507
-
Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
-
Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996;2:1361-6.
-
(1996)
Nat Med
, vol.2
, pp. 1361-1366
-
-
Strand, S.1
Hofmann, W.J.2
Hug, H.3
-
18
-
-
0030895084
-
Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
-
Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997;99:1173-8.
-
(1997)
J Clin Invest
, vol.99
, pp. 1173-1178
-
-
Saas, P.1
Walker, P.R.2
Hahne, M.3
-
19
-
-
0030960010
-
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
-
Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94:6420-5.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 6420-6425
-
-
Shiraki, K.1
Tsuji, N.2
Shioda, T.3
-
20
-
-
0032103027
-
FasL expression in oesophageal carcinoma is associated with depletion of tumor infiltrating lymphocytes
-
Bennett MW, O'Connell J, O'Sullivan GC, et al. FasL expression in oesophageal carcinoma is associated with depletion of tumor infiltrating lymphocytes. J Immunol 1998;160:5669-75.
-
(1998)
J Immunol
, vol.160
, pp. 5669-5675
-
-
Bennett, M.W.1
O'Connell, J.2
O'Sullivan, G.C.3
-
21
-
-
0028783367
-
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
-
Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-30.
-
(1995)
J Exp Med
, vol.182
, pp. 1223-1230
-
-
Galle, P.R.1
Hofmann, W.J.2
Walczak, H.3
-
22
-
-
0028919473
-
Expression of the functional soluble form of human fas ligand in activated lymphocytes
-
Tanaka M, Suda T, Takahashi T, et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
-
(1995)
EMBO J
, vol.14
, pp. 1129-1135
-
-
Tanaka, M.1
Suda, T.2
Takahashi, T.3
-
23
-
-
0030850696
-
The Fas counterattack: A molecular mechanism of tumor immune privilege
-
O'Connell J, Bennett MW, O'Sullivan GC, et al. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997;3:294-300.
-
(1997)
Mol Med
, vol.3
, pp. 294-300
-
-
O'Connell, J.1
Bennett, M.W.2
O'Sullivan, G.C.3
-
24
-
-
0031132872
-
Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus
-
Hunt JS, Vassmer D, Ferguson TA, et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997;158:4122-8.
-
(1997)
J Immunol
, vol.158
, pp. 4122-4128
-
-
Hunt, J.S.1
Vassmer, D.2
Ferguson, T.A.3
-
25
-
-
0030584826
-
Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis
-
Eischen CM, Schilling JD, Lynch DH, et al. Fc receptor-injuced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996;156:2693-9.
-
(1996)
J Immunol
, vol.156
, pp. 2693-2699
-
-
Eischen, C.M.1
Schilling, J.D.2
Lynch, D.H.3
-
26
-
-
0029788696
-
Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils
-
Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996;184:429-40.
-
(1996)
J Exp Med
, vol.184
, pp. 429-440
-
-
Liles, W.C.1
Kiener, P.A.2
Ledbetter, J.A.3
-
27
-
-
0030972396
-
Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft
-
Allison J, Georgiou HM, Strasser A, et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft. Proc Natl Acad Sci USA 1997;94:3943-7.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 3943-3947
-
-
Allison, J.1
Georgiou, H.M.2
Strasser, A.3
-
28
-
-
0030842535
-
Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
-
Kang S-M, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-43.
-
(1997)
Nat Med
, vol.3
, pp. 738-743
-
-
Kang, S.-M.1
Schneider, D.B.2
Lin, Z.3
-
29
-
-
0031042972
-
Antitumor effect of locally produced CD95 ligand
-
Seino K, Kayagaki N, Okumura K, et al. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
-
(1997)
Nat Med
, vol.3
, pp. 165-170
-
-
Seino, K.1
Kayagaki, N.2
Okumura, K.3
-
30
-
-
0031472398
-
Gene transfer of Fas ligand induces tumor regression in vivo
-
Arai H, Gordon D, Nabel EG, et al. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997;94:13862-7.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 13862-13867
-
-
Arai, H.1
Gordon, D.2
Nabel, E.G.3
-
31
-
-
0030755435
-
FasL: Too much of a good thing?
-
Lau HT, Stoeckert CJ. FasL: too much of a good thing? Nat Med 1997;3:727-8.
-
(1997)
Nat Med
, vol.3
, pp. 727-728
-
-
Lau, H.T.1
Stoeckert, C.J.2
-
32
-
-
0030853159
-
Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer
-
Zhang H, Yang Y, Horton JL, et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997;100:1951-7.
-
(1997)
J Clin Invest
, vol.100
, pp. 1951-1957
-
-
Zhang, H.1
Yang, Y.2
Horton, J.L.3
-
33
-
-
0021917804
-
Lymphokine-activated killer (LAK) cells: Analysis of factors relevant to the immunotherapy of human cancer
-
Rayner AA, Grimm EA, Lotze MT. Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985;55:1327.
-
(1985)
Cancer
, vol.55
, pp. 1327
-
-
Rayner, A.A.1
Grimm, E.A.2
Lotze, M.T.3
|